Siraj Ali
Overview
Explore the profile of Siraj Ali including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
2022
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Johnson A, Severson E, Gay L, Vergilio J, Elvin J, Suh J, et al.
Oncologist
. 2017 Sep;
22(12):1478-1490.
PMID: 28912153
Background: Pediatric brain tumors are the leading cause of death for children with cancer in the U.S. Incorporating next-generation sequencing data for both pediatric low-grade (pLGGs) and high-grade gliomas (pHGGs)...
22.
Cramer S, Li R, Ali S, Bradley J, Kim H, Pressey J
J Natl Compr Canc Netw
. 2017 Jul;
15(7):868-871.
PMID: 28687574
Primitive myxoid mesenchymal tumor of infancy (PMMTI) is a rare tumor with <20 cases reported to date. Recently PMMTI tumors have been found to harbor internal tandem duplication (ITD), the...
23.
Kulkarni A, Al-Hraishawi H, Simhadri S, Hirshfield K, Chen S, Pine S, et al.
Clin Cancer Res
. 2017 May;
23(18):5631-5638.
PMID: 28539463
Many patients with mutant melanoma treated with BRAF inhibitors experience a rapid response, but ultimately develop resistance. Insight into the mechanism of resistance is critical for development of more effective...
24.
Campregher P, Halley N, Vieira G, Fernandes J, Velloso E, Ali S, et al.
Leuk Lymphoma
. 2017 May;
58(12):2969-2972.
PMID: 28509585
No abstract available.
25.
Wang V, Young L, Ali S, Miller V, Urisman A, Wolfe J, et al.
Oncologist
. 2017 May;
22(7):768-773.
PMID: 28507205
Key Points: To our knowledge, this index case represents the first reported translocation identified in an atypical carcinoid tumor.Liquid biopsy such as circulating tumor DNA is a feasible alternative platform...
26.
Lee L, Gasilina A, Roychoudhury J, Clark J, McCormack F, Pressey J, et al.
JCI Insight
. 2017 Feb;
2(3):e89473.
PMID: 28194436
Many patients with histiocytic disorders such as Langerhans cell histiocytosis (LCH) or Erdheim-Chester disease (ECD) have treatment-refractory disease or suffer recurrences. Recent findings of gene mutations in histiocytoses have generated...
27.
RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients
Sarfaty M, Moore A, Neiman V, Dudnik E, Ilouze M, Gottfried M, et al.
Clin Lung Cancer
. 2017 Jan;
18(4):e223-e232.
PMID: 28082048
Background: RET (rearranged during transfection) fusions have been reported in 1% to 2% of lung adenocarcinoma (LADC) cases. In contrast, KIF5B-RET and CCDC6-RET fusion genes have been identified in 70%...
28.
Chmielecki J, Bailey M, He J, Elvin J, Vergilio J, Ramkissoon S, et al.
Cancer Res
. 2017 Jan;
77(2):509-519.
PMID: 28069802
Pediatric cancers are generally characterized by low mutational burden and few recurrently mutated genes. Recent studies suggest that genomic alterations may help guide treatment decisions and clinical trial selection. Here,...
29.
Okimoto R, Breitenbuecher F, Olivas V, Wu W, Gini B, Hofree M, et al.
Nat Genet
. 2016 Nov;
49(1):87-96.
PMID: 27869830
Metastasis is the leading cause of death in people with lung cancer, yet the molecular effectors underlying tumor dissemination remain poorly defined. Through the development of an in vivo spontaneous...
30.
Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley R, Wang K, et al.
Cancer
. 2016 Sep;
122(24):3838-3847.
PMID: 27622582
Background: Biliary tract cancers (BTCs) typically present at an advanced stage, and systemic chemotherapy is often of limited benefit. Methods: Hybrid capture-based comprehensive genomic profiling (CGP) was performed for 412...